<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002179</url>
  </required_header>
  <id_info>
    <org_study_id>246G</org_study_id>
    <secondary_id>MK-0639</secondary_id>
    <nct_id>NCT00002179</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection</brief_title>
  <official_title>A Multiclinic, Open Study to Evaluate the Ability of the Combination of Indinavir, Zidovudine and Lamivudine to Result in Sustained Suppression of HIV-1 in Asymptomatic HIV-1 Seropositive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the ability of the combination of indinavir, zidovudine, and lamivudine to&#xD;
      suppress HIV-1 infection as measured by: (1) the maintenance of HIV-1 serum viral RNA below&#xD;
      the limit of detection of the most sensitive validated assay (ultradirect assay) and (2)&#xD;
      absence of evidence of infectious virus in lymph node, cerebrospinal fluid (CSF), peripheral&#xD;
      mononuclear cells (PBMCs), and semen.&#xD;
&#xD;
      It is hypothesized that the administration of indinavir, zidovudine, and lamivudine will&#xD;
      result in:&#xD;
&#xD;
        1. No evidence of infectious virus in lymph node tissue, CSF, PBMCs, and semen samples in&#xD;
           50% of patients who have undetectable viral RNA by the most sensitive validated assay&#xD;
           available (ultradirect assay) for at least 48 weeks.&#xD;
&#xD;
        2. Sustained suppression of HIV-1 infection as measured by a decrease in serum viral RNA to&#xD;
           below the limit of detection of the ultradirect assay for at least 48 weeks in at least&#xD;
           25% of patients.&#xD;
&#xD;
        3. Suppression of HIV-1 infection as measured by a decrease in serum viral RNA to below the&#xD;
           limit of detection of the standard Amplicor assay (i.e., negative) in at least 90% of&#xD;
           patients by Week 16.&#xD;
&#xD;
        4. Suppression of HIV-1 infection, suggesting eradication of the virus as measured by&#xD;
           maintenance of serum viral RNA to below the limit of detection of the ultradirect assay&#xD;
           for at least 24 weeks after discontinuation of indinavir, zidovudine, and lamivudine in&#xD;
           patients who have maintained this level of suppression for at least 120 weeks on&#xD;
           therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that the administration of indinavir, zidovudine, and lamivudine will&#xD;
      result in:&#xD;
&#xD;
        1. No evidence of infectious virus in lymph node tissue, CSF, PBMCs, and semen samples in&#xD;
           50% of patients who have undetectable viral RNA by the most sensitive validated assay&#xD;
           available (ultradirect assay) for at least 48 weeks.&#xD;
&#xD;
        2. Sustained suppression of HIV-1 infection as measured by a decrease in serum viral RNA to&#xD;
           below the limit of detection of the ultradirect assay for at least 48 weeks in at least&#xD;
           25% of patients.&#xD;
&#xD;
        3. Suppression of HIV-1 infection as measured by a decrease in serum viral RNA to below the&#xD;
           limit of detection of the standard Amplicor assay (i.e., negative) in at least 90% of&#xD;
           patients by Week 16.&#xD;
&#xD;
        4. Suppression of HIV-1 infection, suggesting eradication of the virus as measured by&#xD;
           maintenance of serum viral RNA to below the limit of detection of the ultradirect assay&#xD;
           for at least 24 weeks after discontinuation of indinavir, zidovudine, and lamivudine in&#xD;
           patients who have maintained this level of suppression for at least 120 weeks on&#xD;
           therapy.&#xD;
&#xD;
      All patients receive indinavir plus zidovudine plus lamivudine for at least 96 weeks. If&#xD;
      there is no evidence of infectious virus, and patients continue to have serum viral RNA&#xD;
      levels below the limit of detection of the ultradirect assay for at least 96 weeks, therapy&#xD;
      is continued for an additional 24 weeks. However, during this additional 24 weeks of therapy&#xD;
      patients may continue to receive this triple combination drug regimen or make changes to this&#xD;
      drug regimen treatment by reducing their number of antiretroviral agents. After 120 weeks, if&#xD;
      patients continue to have serum viral RNA levels below the limit of detection of the&#xD;
      ultradirect assay, patients discontinue all antiretroviral therapy. However, if there is any&#xD;
      evidence of infectious virus, as outlined above, patients do not discontinue therapy.&#xD;
      Patients who develop detectable serum viral RNA following discontinuation of therapy are&#xD;
      given the option to reinitiate therapy with the triple combination of indinavir, zidovudine&#xD;
      and lamivudine. NOTE: Patients who develop an intolerance to zidovudine may use stavudine at&#xD;
      doses per body weight at the direction of the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>200</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV-1 seropositive status.&#xD;
&#xD;
          -  CD4 count &gt;= 500 cells/mm3.&#xD;
&#xD;
          -  Serum viral RNA level &gt; 1000 copies/ml.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Previous antiretroviral therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>352942050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Community Research Consortium</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Univ School of Medicine / AIDS Program</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr / Infect Dis</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>606123832</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard (Massachusetts Gen Hosp)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hosp</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Community Health Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Med Ctr - East Campus</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp / SUNY at Stony Brook / AIDS TMT Unit</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>117948153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt Treatment Ctr</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown Univ / Miriam Hosp</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Paul's Hosp</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Gen Hosp</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Semen</keyword>
  <keyword>Monocytes</keyword>
  <keyword>HIV-1</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Lymph Nodes</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Indinavir</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Indinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

